Stay updated on ADG126 + Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ADG126 + Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ADG126 + Pembrolizumab in Solid Tumors Clinical Trial page
- Check3 days agoChange DetectedVersion v3.3.4 was released on 2026-01-07 with updates to core sections including Contacts/Locations, Eligibility, Outcome Measures, Arms and Interventions, Study Design, Study Description, and Study Status. The prior revision v3.3.3 dated 2025-06-04 is removed.SummaryDifference1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedNew history entry added: Revision: v3.3.3; removed items from the history include HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page shows a minor site revision from v3.2.0 to v3.3.2 with no changes to trial data, study descriptions, or links. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedRemoved the banner about government funding lapses and related operating status updates on the page.SummaryDifference0.8%

- Check74 days agoChange DetectedThe update shows minor visual adjustments to the Record History page and the version list; there are no changes to core trial data such as status, description, or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check103 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference12%

Stay in the know with updates to ADG126 + Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADG126 + Pembrolizumab in Solid Tumors Clinical Trial page.